Terns Pharmaceuticals director sells over $560k in company stock By Investing.com

Director Carl L. Gordon of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has recently sold a significant portion of his holdings in the company. According to the latest filings, Gordon parted with a total of 56,164 shares of common stock at a price of $10.00 per share, resulting in a transaction value of $561,640.

The sales occurred over two days, with the first set of transactions taking place on July 15, 2024, and the subsequent sales on July 16, 2024. Post-transaction, Gordon’s ownership in Terns Pharmaceuticals has been adjusted to reflect the shares sold, yet he still retains a substantial number of shares indirectly.

The shares sold were held by different entities associated with OrbiMed, a healthcare investment firm. Footnotes in the filing indicate that these shares are owned by various OrbiMed funds, such as OrbiMed Private Investments VII, LP, OrbiMed Asia Partners III, L.P., and OrbiMed Genesis Master Fund, L.P. Gordon, along with other members of the management committee at OrbiMed, disclaims beneficial ownership of the shares held by these funds, except to the extent of their pecuniary interest therein.

The transactions were made public through a Form 4 filing with the Securities and Exchange Commission, which provides transparency into the trading activities of a company’s insiders. It is worth noting that the shares were sold at a uniform price of $10.00 per share, a detail that investors often monitor as it can provide insight into the insiders’ view of the stock’s value.

Investors and market watchers pay close attention to insider transactions as they can provide valuable signals about a company’s health and future prospects. While the reasons behind Gordon’s sale are not disclosed in the filing, the move has certainly caught the attention of the investment community.

Terns Pharmaceuticals, with headquarters in Foster City, California, operates within the pharmaceutical preparations industry and continues to be a subject of interest for those following healthcare and biotech investments.

In other recent news, Terns Pharmaceuticals has been making significant strides in the biopharmaceutical landscape. The company’s lead programs, TERN-701 for chronic myeloid leukemia (CML) and TERN-601 for obesity, are showing promising potential. The CARDINAL trial for TERN-701, which is expected to deliver results in the second half of 2024, is particularly noteworthy. This trial is assessing the safety, efficacy, and pharmacokinetics of TERN-701 in previously treated CML patients.

In addition, TERN-601, aimed at obesity treatment, is another asset that could drive the company’s growth. Preliminary safety findings are encouraging, with weight loss data expected in the latter half of 2024. JMP Securities maintains a “MARKET OUTPERFORM” rating for Terns Pharmaceuticals, while BMO Capital Markets Corp. rates the company as “Outperform”.

On another note, Terns Pharmaceuticals has announced recent findings from a Phase 1 study of TERN-701. The interim findings suggest that TERN-701 can be administered once daily with or without food, a significant advantage over current treatments. The company’s financial stability is underlined by a strong cash balance, expected to sustain operations into 2026. These developments underline Terns Pharmaceuticals’ commitment to addressing serious diseases with their portfolio of small-molecule product candidates.

InvestingPro Insights

Following the recent insider transactions by Director Carl L. Gordon at Terns Pharmaceuticals, Inc. (NASDAQ:TERN), investors are keen to understand the company’s financial health and market position. An analysis of real-time data from InvestingPro provides a clearer picture of the company’s current standing.

Terns Pharmaceuticals holds a market capitalization of $627.37 million, reflecting its valuation in the market as of the latest data. Despite the company’s significant returns over recent periods, with a one-week price total return of 15.59% and an impressive three-month price total return of 110.02%, the P/E ratio stands at -7.51, indicating that the company is not currently profitable.

Adding to the complexity of Terns Pharmaceuticals’ outlook are the InvestingPro Tips highlighting that analysts have revised their earnings upwards for the upcoming period, suggesting optimism for the company’s future financial performance. Moreover, the company’s stock price has been known to often move in the opposite direction of the market, which could present unique opportunities for investors.

For those interested in delving deeper into the company’s prospects, there are additional InvestingPro Tips available. These tips include insights on the company’s cash position, debt levels, and profitability outlook. Currently, there are 13 more tips listed on InvestingPro that could provide valuable guidance for investors. To explore these further insights and tips, use the promo code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription at InvestingPro.

While insider sales such as Gordon’s can signal various strategic moves, the broader financial data and market trends provided by InvestingPro help to paint a more comprehensive picture of Terns Pharmaceuticals’ position in the pharmaceutical preparations industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.